Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Marcelo Bueno de Camargo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Pharmaceutical Sciences, University of Sorocaba, São Paulo, Brazil. Hauptthemen laut MEDLINE: Drug Hypersensitivity Syndrome, Anti-Bacterial Agents, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background and Purpose This study investigated the association between the use of antibiotics and the occurrence of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome, a rare and serious adverse event characterized by eosinophilia and acute skin rash. Without early diagnosis, the syndrome can lead to complications or even death.
Methods
In 2020, the Brazilian National Health Surveillance Agency (Anvisa) made available a system for reporting adverse drug events, called VigiMed. Reports of adverse events registered on this system between December 1, 2018 and December 31, 2022, were analyzed. Reporting odds ratio (ROR), together with the respective 95% confidence intervals (95% CI), was calculated as a measure of the association between antibiotics and DRESS syndrome.
Results
A total of 160,101 reports of adverse drug events were analyzed, with 136 suspected cases of DRESS syndrome. Compared with other drugs, the following frequencies of suspected DRESS syndrome were observed for the use of any antibiotic (ROR: 4.8; 95% CI: 3.3–7.0), meropenem (ROR: 13.0; 95% CI: 8.0–21.0), vancomycin (ROR: 11.5; 95% CI: 7.4–17.6), ampicillin (ROR: 6.8; 95% CI: 2.1–21.8), amoxicillin (ROR: 4.7; 95% CI: 1.5–15.0), cefepime (ROR: 4.3; 95% CI: 1.3–13.6), piperacillin + tazobactam (ROR: 2.5; 95% CI: 1.1–5.8) and ceftriaxone (ROR: 2.4; 95% CI: 1.1–5.1). The ROR for DRESS syndrome and the use of oxacillin was 2.7 with a wide 95% CI (0.7–11.1).
Conclusions
An association was observed between reports of DRESS syndrome and the use of antibiotics, particularly those routinely used in a hospital setting. Although there is a potential risk of underreporting or unattributed causality, the information obtained in this study is valuable for the analysis of rare adverse reactions. Given the seriousness of the findings, further studies should be conducted to obtain more accurate information about this adverse reaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program in Pharmaceutical Sciences, University of Sorocaba, São Paulo, Brazil.
- Faculty of Medicine, University of Porto, Porto, Portugal.
- University of Brasília (UNB), Brasilia, Brazil.
ORCID-Profile: Marcelo Bueno de Camargo, Inês Ribeiro-Vaz, Cristiane de Cássia Bergamaschi, Marcus Tolentino Silva
Zitieren
APA
de Camargo, M. B., Ribeiro-Vaz, I., de Cássia Bergamaschi, C., & Silva, M. T. (2025). Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70128
Vancouver
de Camargo MB, Ribeiro-Vaz I, de Cássia Bergamaschi C, Silva MT. Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70128
BibTeX
@article{deCamargo2025,
author = {de Camargo, Marcelo Bueno and Ribeiro-Vaz, Inês and de Cássia Bergamaschi, Cristiane and Silva, Marcus Tolentino},
title = {Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70128}
}
EUVIMED